# Netgear, Inc.: financial statements, quarterly

NTGR · Nasdaq · CIK 1122904 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ntgr.md) · [Financials](/companies/ntgr/financials.md) · [Filings](/companies/ntgr/filings.md) · [Insiders](/companies/ntgr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntgr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [198](/filings/0000950170-24-120104.md) | [189 d](/filings/0001193125-26-051346.md) | [165](/filings/0000950170-25-062803.md) | [144](/filings/0000950170-25-101450.md) | [183](/filings/0001193125-25-260790.md) | [182 d](/filings/0001193125-26-051346.md) | [162](/filings/0001193125-26-201463.md) | [171](/filings/0001193125-26-338402.md) | [185](/filings/0001193125-25-260790.md) | [182 d](/filings/0001193125-26-051346.md) | [159](/filings/0001193125-26-201463.md) | [169](/filings/0001193125-26-338402.md) |
| Cost of revenue | $m | [129](/filings/0000950170-24-120104.md) | [123 d](/filings/0001193125-26-051346.md) | [116](/filings/0000950170-25-062803.md) | [112](/filings/0000950170-25-101450.md) | [126](/filings/0001193125-25-260790.md) | [123 d](/filings/0001193125-26-051346.md) | [106](/filings/0001193125-26-201463.md) | [107](/filings/0001193125-26-338402.md) | [112](/filings/0001193125-25-260790.md) | [109 d](/filings/0001193125-26-051346.md) | [94.5](/filings/0001193125-26-201463.md) | [101](/filings/0001193125-26-338402.md) |
| Gross profit | $m | [68.9](/filings/0000950170-24-120104.md) | [65.6 d](/filings/0001193125-26-051346.md) | [48.2](/filings/0000950170-25-062803.md) | [31.8](/filings/0000950170-25-101450.md) | [56.5](/filings/0001193125-25-260790.md) | [59.4 d](/filings/0001193125-26-051346.md) | [56.3](/filings/0001193125-26-201463.md) | [64.0](/filings/0001193125-26-338402.md) | [72.3](/filings/0001193125-25-260790.md) | [73.6 d](/filings/0001193125-26-051346.md) | [64.3](/filings/0001193125-26-201463.md) | [67.8](/filings/0001193125-26-338402.md) |
| Research and development | $m | [20.7](/filings/0000950170-24-120104.md) | [19.6 d](/filings/0001193125-26-051346.md) | [20.2](/filings/0000950170-25-062803.md) | [19.9](/filings/0000950170-25-101450.md) | [20.9](/filings/0001193125-25-260790.md) | [20.1 d](/filings/0001193125-26-051346.md) | [18.3](/filings/0001193125-26-201463.md) | [20.8](/filings/0001193125-26-338402.md) | [23.3](/filings/0001193125-25-260790.md) | [23.2 d](/filings/0001193125-26-051346.md) | [21.7](/filings/0001193125-26-201463.md) | [22.3](/filings/0001193125-26-338402.md) |
| Operating income | $m | [(0.6)](/filings/0000950170-24-120104.md) | [(2.9) d](/filings/0001193125-26-051346.md) | [(21.6)](/filings/0000950170-25-062803.md) | [(46.9)](/filings/0000950170-25-101450.md) | [95.8](/filings/0001193125-25-260790.md) | [(15.1) d](/filings/0001193125-26-051346.md) | [(12.8)](/filings/0001193125-26-201463.md) | [(9.5)](/filings/0001193125-26-338402.md) | [(7.1)](/filings/0001193125-25-260790.md) | [(4.7) d](/filings/0001193125-26-051346.md) | [(13.6)](/filings/0001193125-26-201463.md) | [(8.4)](/filings/0001193125-26-338402.md) |
| Income tax | $m | [86.4](/filings/0000950170-24-120104.md) | [1.2 d](/filings/0001193125-26-051346.md) | [(0.1)](/filings/0000950170-25-062803.md) | [1.0](/filings/0000950170-25-101450.md) | [14.2](/filings/0001193125-25-260790.md) | [(2.6) d](/filings/0001193125-26-051346.md) | [1.4](/filings/0001193125-26-201463.md) | [0.9](/filings/0001193125-26-338402.md) | [0.7](/filings/0001193125-25-260790.md) | [(1.9) d](/filings/0001193125-26-051346.md) | [1.0](/filings/0001193125-26-201463.md) | [0.5](/filings/0001193125-26-338402.md) |
| Net income | $m | [(84.8)](/filings/0000950170-24-120104.md) | [(1.7) d](/filings/0001193125-26-051346.md) | [(18.7)](/filings/0001193125-25-260790.md) | [(45.2)](/filings/0001193125-25-260790.md) | [85.1](/filings/0001193125-25-260790.md) | [(8.9) d](/filings/0001193125-26-051346.md) | [(6.0)](/filings/0001193125-26-338402.md) | [(6.4)](/filings/0001193125-26-338402.md) | [(4.8)](/filings/0001193125-25-260790.md) | [(0.7) d](/filings/0001193125-26-051346.md) | [(13.0)](/filings/0001193125-26-338402.md) | [(7.3)](/filings/0001193125-26-338402.md) |
| Diluted EPS | $ per share | [(2.87)](/filings/0000950170-24-120104.md) | not reported | [(0.63)](/filings/0000950170-25-062803.md) | [(1.56)](/filings/0000950170-25-101450.md) | [2.90](/filings/0001193125-25-260790.md) | not reported | [(0.21)](/filings/0001193125-26-201463.md) | [(0.22)](/filings/0001193125-26-338402.md) | [(0.17)](/filings/0001193125-25-260790.md) | not reported | [(0.47)](/filings/0001193125-26-201463.md) | [(0.27)](/filings/0001193125-26-338402.md) |
| Basic EPS | $ per share | [(2.87)](/filings/0000950170-24-120104.md) | not reported | [(0.63)](/filings/0000950170-25-062803.md) | [(1.56)](/filings/0000950170-25-101450.md) | [2.96](/filings/0001193125-25-260790.md) | not reported | [(0.21)](/filings/0001193125-26-201463.md) | [(0.22)](/filings/0001193125-26-338402.md) | [(0.17)](/filings/0001193125-25-260790.md) | not reported | [(0.47)](/filings/0001193125-26-201463.md) | [(0.27)](/filings/0001193125-26-338402.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-10-01) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [131](/filings/0000950170-23-058796.md) | [177](/filings/0000950170-25-021413.md) | [173](/filings/0000950170-24-053040.md) | [177](/filings/0000950170-24-089944.md) | [274](/filings/0000950170-24-120104.md) | [286](/filings/0001193125-26-051346.md) | [270](/filings/0001193125-26-201463.md) | [241](/filings/0001193125-26-338402.md) | [203](/filings/0001193125-25-260790.md) | [210](/filings/0001193125-26-338402.md) | [183](/filings/0001193125-26-201463.md) | [174](/filings/0001193125-26-338402.md) |
| Current assets | $m | [741](/filings/0000950170-23-058796.md) | [748](/filings/0000950170-25-021413.md) | [704](/filings/0000950170-24-053040.md) | [658](/filings/0000950170-24-089944.md) | [769](/filings/0000950170-24-120104.md) | [758](/filings/0001193125-26-051346.md) | [724](/filings/0000950170-25-062803.md) | [699](/filings/0000950170-25-101450.md) | [682](/filings/0001193125-25-260790.md) | [673](/filings/0001193125-26-338402.md) | [643](/filings/0001193125-26-201463.md) | [634](/filings/0001193125-26-338402.md) |
| Total assets | $m | [842](/filings/0000950170-23-058796.md) | [847](/filings/0000950170-25-021413.md) | [801](/filings/0000950170-24-053040.md) | [754](/filings/0000950170-24-089944.md) | [863](/filings/0000950170-24-120104.md) | [850](/filings/0001193125-26-051346.md) | [814](/filings/0000950170-25-062803.md) | [804](/filings/0000950170-25-101450.md) | [811](/filings/0001193125-25-260790.md) | [836](/filings/0001193125-26-338402.md) | [802](/filings/0001193125-26-201463.md) | [789](/filings/0001193125-26-338402.md) |
| Current liabilities | $m | [260](/filings/0000950170-23-058796.md) | [264](/filings/0000950170-25-021413.md) | [244](/filings/0000950170-24-053040.md) | [253](/filings/0000950170-24-089944.md) | [271](/filings/0000950170-24-120104.md) | [270](/filings/0001193125-26-051346.md) | [242](/filings/0000950170-25-062803.md) | [243](/filings/0000950170-25-101450.md) | [239](/filings/0001193125-25-260790.md) | [250](/filings/0001193125-26-338402.md) | [249](/filings/0001193125-26-201463.md) | [255](/filings/0001193125-26-338402.md) |
| Total liabilities | $m | [310](/filings/0000950170-23-058796.md) | [312](/filings/0000950170-25-021413.md) | [290](/filings/0000950170-24-053040.md) | [295](/filings/0000950170-24-089944.md) | [312](/filings/0000950170-24-120104.md) | [309](/filings/0001193125-26-051346.md) | [280](/filings/0000950170-25-062803.md) | [280](/filings/0000950170-25-101450.md) | [304](/filings/0001193125-25-260790.md) | [338](/filings/0001193125-26-338402.md) | [331](/filings/0001193125-26-201463.md) | [332](/filings/0001193125-26-338402.md) |
| Shareholders' equity | $m | [533](/filings/0000950170-24-120104.md) | [535](/filings/0001193125-26-051346.md) | [511](/filings/0001193125-25-260790.md) | [459](/filings/0001193125-25-260790.md) | [550](/filings/0001193125-25-260790.md) | [541](/filings/0001193125-26-338402.md) | [534](/filings/0001193125-26-338402.md) | [523](/filings/0001193125-26-338402.md) | [507](/filings/0001193125-25-260790.md) | [498](/filings/0001193125-26-338402.md) | [471](/filings/0001193125-26-338402.md) | [456](/filings/0001193125-26-338402.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [26.1 d](/filings/0000950170-24-120104.md) | [56.3 d](/filings/0001193125-26-051346.md) | [17.2](/filings/0000950170-25-062803.md) | [18.4 d](/filings/0000950170-25-101450.md) | [108 d](/filings/0001193125-25-260790.md) | [21.5 d](/filings/0001193125-26-051346.md) | [(8.7)](/filings/0001193125-26-201463.md) | [(1.8) d](/filings/0001193125-26-338402.md) | [(7.4) d](/filings/0001193125-25-260790.md) | [19.5 d](/filings/0001193125-26-051346.md) | [1.6](/filings/0001193125-26-201463.md) | [(10.2) d](/filings/0001193125-26-338402.md) |
| Capital expenditure | $m | [2.0 d](/filings/0000950170-24-120104.md) | [2.2 d](/filings/0001193125-26-051346.md) | [2.5](/filings/0000950170-25-062803.md) | [2.3 d](/filings/0000950170-25-101450.md) | [1.7 d](/filings/0001193125-25-260790.md) | [2.5 d](/filings/0001193125-26-051346.md) | [1.4](/filings/0001193125-26-201463.md) | [3.5 d](/filings/0001193125-26-338402.md) | [9.7 d](/filings/0001193125-25-260790.md) | [5.9 d](/filings/0001193125-26-051346.md) | [3.8](/filings/0001193125-26-201463.md) | [1.5 d](/filings/0001193125-26-338402.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-120104.md) | [0.0 d](/filings/0001193125-26-051346.md) | [11.4](/filings/0000950170-25-062803.md) | [10.0 d](/filings/0000950170-25-101450.md) | [1.5 d](/filings/0001193125-25-260790.md) | [10.2 d](/filings/0001193125-26-051346.md) | [8.2](/filings/0001193125-26-201463.md) | [7.5 d](/filings/0001193125-26-338402.md) | [20.0 d](/filings/0001193125-25-260790.md) | [15.0 d](/filings/0001193125-26-051346.md) | [20.2](/filings/0001193125-26-201463.md) | [12.9 d](/filings/0001193125-26-338402.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-02) | Q1 FY2023 (2023-04-02) | Q2 FY2023 (2023-07-02) | Q3 FY2023 (2023-10-01) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.0](/filings/0000950170-23-058796.md) | [29.0](/filings/0000950170-24-053040.md) | [29.3](/filings/0000950170-24-089944.md) | [29.5](/filings/0000950170-24-120104.md) | [29.4](/filings/0000950170-25-062803.md) | [28.9](/filings/0000950170-25-101450.md) | [29.4](/filings/0001193125-25-260790.md) | [28.7](/filings/0001193125-26-201463.md) | [28.9](/filings/0001193125-26-338402.md) | [28.6](/filings/0001193125-25-260790.md) | [28.0](/filings/0001193125-26-201463.md) | [27.0](/filings/0001193125-26-338402.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 27,179,021 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338402.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.